The FDA approval of UF's AAV technology in voretigene neparvovec (Luxturna) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy almost 4 years ago marked a turning point in gene therapy.
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.
FDA's Cellular, Tissue, and Gene Therapies Advisory Committee experts prepare for a two-day meeting to talk about high-dose that gene therapy developers and investigators are allowed to give patients in each trial.
StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, announced the closing of an oversubscribed Series B funding round, which raised $81.5 million.
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.